A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

266

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

July 8, 2020

Study Completion Date

July 8, 2020

Conditions
SchizophreniaBipolar I Disorder
Interventions
DRUG

Aripiprazole

Administered as an intramuscular (IM) depot injection.

DRUG

Aripiprazole

Administered as an IM depot injection.

Trial Locations (19)

20877

CBH Health, Gaithersburg

29407

Carolina Clinical Trials, Charleston

30331

Atlanta Center for Medical Research - Atlanta, Atlanta

33016

Segal Institute For Clinical Research - West Broward Outpatient Clinic, Miami Lakes

33024

Research Centers of America, Hollywood

45417

Midwest Clinical Research Center, Dayton

63141

St. Louis Clinical Trials, St Louis

72211

Woodland International Research Group, Little Rock

72758

Woodland International Research Group, Rogers

78754

Community Clinical Research, Austin

89102

Altea Research Institute - Las Vegas, Las Vegas

90502

Collaborative Neuroscience Network - South Bay, Torrance

90706

CITrials - Bellflower, Bellflower

91206

California Clinical Trials Medical Group, Glendale

91945

Synergy Research Centers, Lemon Grove

92102

California Neuropsychopharmacology Clinical Research Institute San Diego, San Diego

92845

Collaborative Neuroscience Network, Garden Grove

92868

NRC Research Institute, Orange

08009

Hassman Research Institute, Marlton

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT04030143 - A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder | Biotech Hunter | Biotech Hunter